[144] Ascendis Pharma A/S SEC Filing

Rhea-AI Filing Summary

Ascendis Pharma A/S filed a Form 144 reporting a proposed sale of 19,460 ordinary shares on 05/11/2026 through Citigroup Global Markets. The filing shows an aggregate value of $4,641,021.92 and lists the seller as a Share Plan Account tied to Ascendis Pharma A/S; the method is labeled Compensation.

The excerpt also records a prior sale of 10,277 shares on 03/02/2026 with an aggregate amount of $2,407,985.38 in the past three months.

Insights

Securities Compliance Attorney

Form 144 notifies the market of an intended sale by a company-related share plan account.

The filing lists 19,460 ordinary shares proposed to be sold on 05/11/2026 through Citigroup Global Markets, labeled as Compensation. Form 144 is a notice required when insider holdings are to be sold under Rule 144 or similar resale conditions.

Timing and exact settlement mechanics are not shown in the excerpt; subsequent broker reports or Form 4/Form 5 filings may provide completed sale details.

Form 144 Filer Information	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 144 NOTICE OF PROPOSED SALE OF SECURITIES PURSUANT TO RULE 144 UNDER THE SECURITIES ACT OF 1933
FORM 144

144: Filer Information

Filer CIK
Filer CCC
Is this a LIVE or TEST Filing?	LIVE TEST
Submission Contact Information
Name
Phone
E-Mail Address

144: Issuer Information

Name of Issuer

SEC File Number

Address of Issuer

Phone

Name of Person for Whose Account the Securities are To Be Sold

See the definition of "person" in paragraph (a) of Rule 144. Information is to be given not only as to the person for whose account the securities are to be sold but also as to all other persons included in that definition. In addition, information shall be given as to sales by all persons whose sales are required by paragraph (e) of Rule 144 to be aggregated with sales for the account of the person filing this notice.

Relationship to Issuer

Relationship to Issuer

144: Securities Information

Title of the Class of Securities To Be Sold	Name and Address of the Broker	Number of Shares or Other Units To Be Sold	Aggregate Market Value	Number of Shares or Other Units Outstanding	Approximate Date of Sale	Name the Securities Exchange
ORDINARY SHARES	CITIGROUP GLOBAL MARKETS 390 GREENWICH ST NEW YORK NY 10013	19460	4641021.92	61977408	05/11/2026	NASDAQ

Furnish the following information with respect to the acquisition of the securities to be sold and with respect to the payment of all or any part of the purchase price or other consideration therefor:

144: Securities To Be Sold

Title of the Class	Date you Acquired	Nature of Acquisition Transaction	Name of Person from Whom Acquired	Is this a Gift?	Date Donor Acquired	Amount of Securities Acquired	Date of Payment	Nature of Payment *
ORDINARY SHARES	05/11/2026	SHARE PLAN ACCOUNT	ASCENDIS PHARMA A/S			19460	05/11/2026	COMPENSATION

* If the securities were purchased and full payment therefor was not made in cash at the time of purchase, explain in the table or in a note thereto the nature of the consideration given. If the consideration consisted of any note or other obligation, or if payment was made in installments describe the arrangement and state when the note or other obligation was discharged in full or the last installment paid.

Furnish the following information as to all securities of the issuer sold during the past 3 months by the person for whose account the securities are to be sold.

144: Securities Sold During The Past 3 Months

Name and Address of Seller	Title of Securities Sold	Date of Sale	Amount of Securities Sold	Gross Proceeds
JENSEN FLEMMING STEEN TUBORG BOULEVARD 12 HELLERUP G7 DK2900	ORDINARY SHARES	03/02/2026	10277	2407985.38

144: Remarks and Signature

Remarks

Date of Notice

ATTENTION:

The person for whose account the securities to which this notice relates are to be sold hereby represents by signing this notice that he does not know any material adverse information in regard to the current and prospective operations of the Issuer of the securities to be sold which has not been publicly disclosed. If such person has adopted a written trading plan or given trading instructions to satisfy Rule 10b5-1 under the Exchange Act, by signing the form and indicating the date that the plan was adopted or the instruction given, that person makes such representation as of the plan adoption or instruction date.

Signature

ATTENTION: Intentional misstatements or omission of facts constitute Federal Criminal Violations (See 18 U.S.C. 1001)